Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altamira Therapeutics Ltd
(NQ:
CYTO
)
1.560
UNCHANGED
Streaming Delayed Price
Updated: 3:51 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Altamira Therapeutics Ltd
< Previous
1
2
3
4
Next >
Altamira Therapeutics Provides Update on Bentrio Program
September 27, 2021
- Building Bentrio™ brand and expanding in European markets - 510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA") - Distributors signed up...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program
September 21, 2021
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
September 08, 2021
- Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 - Enrollment in Phase 2 trial of AM-125...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
August 06, 2021
- Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) - New data demonstrate protective effects in viral infections...
From
Altamira Therapeutics
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
Death
Intellectual Property
Legal
Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
August 03, 2021
HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.